Thyroid carcinoma
Conditions
Interventions
Not applicable.
Sponsors
Radboudumc
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: In general: Subjects should be at least 18 years old and mentally competent Patients with TC: Group 1: -newly diagnosed patients with TC that are therapy naïve and are planned to receive conventional treatment by surgery followed by RAI -no evidence of local or distant metastases Group 2: -patients with TC with evidence of distant metastases (either newly diagnosed patients who are therapy naïve or patients with persistent or recurrent disease) -at least 4 months since the previous treatment with RAI (in the patients who have had this treatment in the past) Controls: Group 3: -patients with MNG that are euthyroid and in which the decision has been taken to undergo surgery because of obstructive symptoms or for cosmetic reasons Group 4: -patients with MNG that are euthyroid and in which the decision has been taken to undergo RAI because of obstructive symptoms. Group 5: -healthy individuals who are euthyroid and have no evidence of thyroid disease.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: -Mentally incompetent -Pregnant or breastfeeding -Known inflammatory or infectious diseases or an immunosuppressive status; -Using medication interfering with the immune system -Reduced platelets counts or other conditions associated with an increased risk of bleeding -Severe comorbidities: other active malignancy (except for basal cell carcinoma) -Serious psychiatric pathology -A self-reported alcohol consumption of >21 units per week
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcriptional and epigenetic signature and function of TAMs, BM myeloid progenitors and circulating macrophages before and after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence of circulating tumor cells (CTC) and changes in circulating metabolites (either tumor-derived or tumor-induced) concentrations (metabolomics) associated with the functional reprogramming of the immune cells. | — |
Contacts
Public ContactWanda Raadt, de
PO Box 30016
Outcome results
None listed